stockrow
Saturday 7 November 2026
Export SER’s income statement to Excel — free account
Serina Therapeutics, Inc.
Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.
- Revenue
- +2,500.0%
- EPS
- +16.7%
- Free cash flow
- −76.8%
Quarter to June 2026, against a year earlier
1.40
0.25
−15.15%
Follow SER
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
217.81% | 858.45% | (298.55%) | (306.22%) | |
| (188.46%) | (280.54%) | (124.99%) | (136.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(568.83%) | (643.26%) | (103.21%) | (108.66%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.60) | (1.77) | (1.52) | (1.29) | |
Free Cash Flow |
(16.58) | (18.02) | (18.28) | (21.20) | |
Capital Expenditures |
(0.07) | (0.06) | (0.08) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(126.53%) | (302.08%) | (40.49%) | (47.28%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(486.75) | (104.44) | (60.81) | (43.06) | |
Operating CF/Net income |
0.88 | 0.94 | 0.86 | 0.89 | |
Depreciation/Fixed assets |
0.19 | 0.28 | 0.42 | 0.57 | |
Capex/Depreciation |
(0.59) | (0.49) | (0.43) | (0.24) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.60) | (1.76) | (1.51) | (1.29) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026